Invention Grant
- Patent Title: EBNA1 inhibitors and their method of use
-
Application No.: US16519590Application Date: 2019-07-23
-
Publication No.: US11242317B2Publication Date: 2022-02-08
- Inventor: Troy E. Messick , Garry R. Smith , Allen B. Reitz , Paul M. Lieberman , Mark E. McDonnell , Yan Zhang , Venkata Velvadapu
- Applicant: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
- Applicant Address: US PA Philadelphia
- Assignee: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
- Current Assignee: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
- Current Assignee Address: US PA Philadelphia
- Agency: Saul Ewing Arnstein & Lehr LLP
- Agent Kathryn Doyle; Domingos Silva
- Main IPC: A61K31/405
- IPC: A61K31/405 ; A61K31/41 ; A61K31/42 ; A61K31/415 ; A61K31/40 ; C07D515/02 ; C07D209/44 ; C07D295/04 ; C07D261/06 ; C07D233/02 ; C07D233/00 ; C07D207/327 ; A61K31/404 ; A61K31/4439 ; A61K31/496 ; A61K31/192 ; A61K31/44 ; C07C229/56 ; C07C255/54 ; C07C255/55 ; C07C211/27 ; C07C217/84 ; C07C233/11 ; C07C233/64 ; C07C233/65 ; C07C235/58 ; C07C311/08 ; C07C311/16 ; C07C311/17 ; C07C317/14 ; C07D235/06 ; C07D403/10 ; C07D239/26 ; C07D409/10 ; C07D417/10 ; C07D471/04 ; C07D487/04 ; C07D209/08 ; C07D295/155 ; C07D213/55 ; C07C53/18 ; C07C63/66 ; C07C65/19 ; C07C65/28 ; C07C229/64 ; C07C317/44 ; C07D207/08 ; C07D207/12 ; C07D207/14 ; C07D207/16 ; C07D211/70 ; C07D213/64 ; C07D213/74 ; C07D215/14 ; C07D231/12 ; C07D249/06 ; C07D277/30 ; C07D307/79 ; C07D333/54 ; C07D401/04 ; C07D401/10
Abstract:
Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.
Public/Granted literature
- US20200181078A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE Public/Granted day:2020-06-11
Information query
IPC分类:
